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Abstract
Background: Positive controls are an integral component of any sensitive molecular diagnostic tool, but this can
be affected, if several mutations are being screened in a scenario of a pandemic or newly emerging disease where
it can be difficult to acquire all the necessary positive controls from the host. This work describes the development
of a synthetic oligo-cassette for positive controls for accurate and highly sensitive diagnosis of several mutations
relevant to influenza virus drug resistance.
Results: Using influenza antiviral drug resistance mutations as an example by employing the utility of synthetic
paired long oligonucleotides containing complementary sequences at their 3’ ends and utilizing the formation of
oligonucleotide dimers and DNA polymerization, we generated ~170bp dsDNA containing several known specific
neuraminidase inhibitor (NAI) resistance mutations. These templates were further cloned and successfully applied
as positive controls in downstream assays.
Conclusion: This approach significantly improved the development of diagnosis of resistance mutations in terms
of time, accuracy, efficiency and sensitivity, which are paramount to monitoring the emergence and spread of
antiviral drug resistant influenza strains. Thus, this may have a significantly broader application in molecular
diagnostics along with its application in rapid molecular testing of all relevant mutations in an event of pandemic.
Background
Recently, the occurrence in humans of infection with
virulent avian influenza A H5N1 and the emergence of
swine origin pandemic influenza A H1N1 2009 strain
have sparked fear of an ongoing pandemic with novel
genetic characters [1-3]. While vaccines remain the
most effective public health strategy for prevention [4,5],
antiviral drugs such as neuraminidase inhibitors (NAIs),
oseltamivir and zanamivir, could play an important role
i nt h er e s p o n s et ot h ee a r l yp h a s e so fap a n d e m i c ,i f
available in sufficient quantities. However, like other
antiviral agents, the emergence of influenza viruses with
reduced susceptibility to the NAI is inevitable during
treatment [1]. To date, strains with altered susceptibility
to NAI have been recovered from approximately 1% of
immunocompetent adult patients [6] and up to 18% of
pediatric patients [7]. In addition, oseltamivir-resistant
influenza A H5N1 and pandemic H1N1 2009 viruses
with the H274Y mutation have been reported from
patients during oseltamivir treatment [8,9].
Significant advances in molecular biology and human
genomic research has paved the way for a host of new
genetic diagnostic tests, including gene sequencing,
detection, identification and genotyping of organisms
using real time polymerase chain reaction (PCR) or
other amplification techniques such as multiplex PCR,
reverse line blot hybridization (RLB) [10], Ligase chain
reaction (LCR), Rolling Circle Amplification (RCA)
[9,11], microarray [12-14]. Sequencing often serves as a
‘gold standard’ for the detection of single nucleotide
polymorphisms, drug resistance mutations or virus/
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any medium, provided the original work is properly cited.bacterial typing [15,16]. However, as sequencing is cum-
bersome, expensive and less likely to detect low preva-
lence mutations (mutations consisting less than 30% of
total populations) [17,18], newer alternative techniques
such as real time PCR and RCA are being employed
[9,15]. To establish molecular assays, positive controls
are a prerequisite to ascertain specificity and sensitivity
[19,20]. However, in many cases it is difficult and cum-
bersome to acquire appropriate positive controls. It is
thus, important to mention that although the commer-
cial oligonucleotide synthesis can generate long oligonu-
cleotides (≥150 mers) and can serve as suitable controls,
there are problems as the oligonucleotide length exceeds
100 nucleobases, the yield of desired products often
becomes limited by side reactions and even modest inef-
ficiencies within the stepwise chemical reactions can
have large effects on the final yield [21].
Further, in the event of an influenza pandemic, drug
resistant strains and their transmission could be clini-
cally highly significant [1], meaning that sensitive and
specific techniques are required for their early and clini-
cally relevant detection. However, due to the low fre-
quency of naturally occurring resistance mutations in
influenza infected patients receiving NA inhibitor treat-
ment, the highly pathogenetic nature of influenza A
H5N1 strains, and the technical complexity and time
consuming nature of generating of NA resistant strains
in vitro, collection of all known resistance mutations as
positive controls is challenging. Therefore, our approach
utilizing the formation of oligonucleotide dimers
between two commercially synthesised long single
stranded DNA templates (~95 bases each), to generate
~170 bp double-stranded artificial DNA templates, con-
taining resistance mutations is not only innovative, but
a more molecularly feasible and durable. In this way, it
offers significant advantages in synthesizing even longer
double stranded DNA templates, which can be used as
positive control templates in molecular diagnostics. In
the present study, we have used these double stranded
artificial DNA templates with all known genetic muta-
tions associated with influenza A drug resistance as a
positive control in the development of a ligase chain
reaction (LCR) for detecting NA inhibitor drug resis-
tance mutations in patient samples.
Results
Generation of ds DNA template from synthetic oligos
After 5 PCR reaction cycles, the products from paired
synthetic long oligos were run on 2% agarose gel,
stained with ethidium bromide and viewed under UV
light. The dsDNA products were clearly visualized at the
size ~170 bp (Figure 1), demonstrating a successful pro-
duction of long ds DNA templates from synthetic oligos.
Cloning of DNA products and sequencing of positive
clones
The PCR products from each paired oligo were cloned
and 5 positive clones were sequenced to validate the
presence of desired mutations. Each sequence was
aligned carefully and compared with the artificial tem-
plate and reference strains. As expected, most sequences
were identical to the artificial template design carrying
resistance mutations (Table 1).
Ligase Chain Reaction in the detection of resistance
mutation
Standard liner template containing resistance mutations
(N1: His274Tyr, H5N1 His274Tyr, N2 Glu119Val, and
N2 Ag292Lys) at various levels were prepared by mixing
wild-type template with template containing resistance
mutations. Each standard template was targeted by four
independent probes specifically recognizing each of the
resistance mutation. After 10 cycles of ligation reaction,
even the presence of low-level of resistance mutation
(~1%) could be detected, as evidence by the formation of
specific dsDNA molecules of about 80-90 bp (Figure 2).
Discussion and Conclusions
Although sequencing serves as a ‘gold standard’ for the
detection of single nucleotide polymorphisms associated
with drug resistance mutations or organism typing
methods [15,16], alternative techniques are being
employed [9,15,22,23]. One impediment to these techni-
ques is the lack of availability of control templates carry-
ing rare mutant variants/alleles or all relevant mutations,
Figure 1 Generation of double stranded DNA templates using
paired synthetic long oligos. After 5 cycles of PCR, the products
were run on 2% agarose gel. The formation of ~170 bp of product
can be clearly visualized.
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Page 2 of 7Table 1 List of artificial templates containing wild type and NA-resistance mutations.
Oligo
name
Oligo Sequence Location in reference
strains
Description
N1 274H
95nt
5’TCGTACAAAATCTTCAAGATCGAAAAGGGAAAGGTTACTAAATCAATAGAGTTGAATGCACCCAATTTTCATTATGAGGAATGTTCCTGTTACCC 3’ H1N1 (CY12306.1, 763-857) Wild Type
N1 274Y
95nt
5’TCGTACAAAATCTTCAAGATCGAAAAGGGAAAGGTTACTAAATCAATAGAGTTGAATGCACCCAATTTTTATTATGAGGAATGTTCCTGTTACCC 3’ H1N1 (CY12306.1, 763-857) Resistance
mutation
N1 274R
96nt
5’TTGATTAAAAGACACCCAAGGTCGATTTGAACCATGCCAGTTGTCCCTGCATACACACATCACTGTGCCAGTGTCTGGGTAACAGGAACATTCCTC3’ H1N1 (CY12306.1, 933-837) Antisense oligo
H5N1
274H
95nt
5’TCACATAAGATCTTCAAAATGGAAAAAGGGAAAGTGGTTAAATCAGTCGAATTGGATGCTCCTAATTATCACTATGAGGAATGCTCCTGTTATCC3’ H5N1 (DQ493076, 694-788) Wild Type
H5N1 274Y
95nt
5’TCACATAAGATCTTCAAAATGGAAAAAGGGAAAGTGGTTAAATCAGTCGAATTGGATGCTCCTAATTATTACTATGAGGAATGCTCCTGTTATCC3’ H5N1 (DQ250165,
694-788)
Resistance
mutation
H5N1 274R
96nt
5’TTGATTGAAAGATACCCATGGCCGATTTGAGCCATGCCAATTATCCCTGCACACACATGTGATTTCGCCGGCATCAGGATAACAGGAGCATTCCTC3’ H5N1 (DQ250165,
864-768)
Antisense oligo
N2-119GLU
90nt
5’TCTAAGGACAATTCGATTCGGCTTTCCGCTGGTGGGGACATCTGGGTGACAAGAGARCCTTATGTGTCATGCGATCCTGACAAGTGTTATC 3’ H3N2 (CY016653,305-395) Wild Type
N2-119Val
90nt
5’TCTAAGGACAATTCGATTCGGCTTTCCGCTGGTGGGGACATCTGGGTGACAAGAGTNCCTTATGTGTCATGCGATCCTGACAAGTGTTATC3’ H3N2 (CY016653,305-395) Resistance
mutation
N2-119GLY
90nt
5’TCTAAGGACAATTCGATTCGGCTTTCCGCTGGTGGGGACATCTGGGTGACAAGAGGNCCTTATGTGTCATGCGATCCTGACAAGTGTTATC3’ H3N2 (CY016653,
305-395)
Polymorphisms
N2-119ALA
90nt
5’TCTAAGGACAATTCGATTCGGCTTTCCGCTGGTGGGGACATCTGGGTGACAAGAGCNCCTTATGTGTCATGCGATCCTGACAAGTGTTATC3’ H3N2 (CY016653,305-395) Polymorphisms
N2-119ASP
90nt
5’TCTAAGGACAATTCGATTCGGCTTTCCGCTGGTGGGGACATCTGGGTGACAAGAGAYCCTTATGTGTCATGCGATCCTGACAAGTGTTATC3’ H3N2 (CY016653,
305-395)
Polymorphisms
N2-119R
98nt
5’CCGATAAGGGGTCCTATCATGTACTGTGTCATTTGAATGCCCGTTGTTTAGTGTTGTTCCCTGTCCAAGGGCAAATTGATAACACTTGTCAGGATCGC3’ H3N2 (CY016653,
472-375)
Antisense oligo
N2-292ARG
89nt
CAGCATGTCGAGGAGTGCTCCTGTTATCCTCGATATCCTGGTGTCAGATGTGTCTGCAGRGACAACTGGAAAGGCTCCAATAGGCCCAT3’ H3N2 (CY016653,
821-909
Wild Type
N2-292LYS
89nt
5’CAGCATGTCGAGGAGTGCTCCTGTTATCCTCGATATCCTGGTGTCAGATGTGTCTGCAARGACAACTGGAAAGGCTCCAATAGGCCCAT3’ H3N2 (CY016653,
821-909
Resistance
mutation
N2-292R
99nt
5’TTTCTGGGTGTGTCTCCAACAAGTCCTGAGCACACATAACTGGAAACAATGCTATAATCCTTTACATTTATATCTACGATGGGCCTATTGGAGCCTTTC3’ H3N2 (CY016653,
987-889
Antisense oligo
1: Synthetic templates containing the wild type, naturally occurring polymorphisms and resistance mutations. These genome locations were indicated in the table according to reference strains.
2: Antisense oligo (R) with complementary sequences at 3’ end were also synthesised and the complementary sequence were shown as underline.
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7which can serve as positive controls in molecular or
multiplex PCR assays simultaneously. In influenza stu-
dies, for example, several single nucleotide mutations
are known to be associated with NA inhibitor resistance
[24,25]. Many of these have been derived from different
in vitro cultures, and currently naturally occurring NAI
resistance appears to be uncommon in some strains.
However, in the event of an influenza pandemic, the use
of NAIs would dramatically increase and thus provide
greater opportunities for resistance to emerge and
spread. Therefore, rapid screening of these mutations,
which would be of great benefit for patient treatment
and the control of disease spread, should be available in
a format that can facilitate simultaneous, rapid and bulk
detection of drug resistance mutations. We were only
able to source wild-type clinical isolates of influenza A
H3N2; known resistant clinical strains were unavailable.
Given that highly pathogenic avian influenza A H5N1
can only be handled in PC4 facilities, we had only lim-
ited access to influenza A H5N1 RNA. This was the
main impediment to molecular assay development for
the detection of drug resistance mutations. Thus, we
endeavored to create artificial templates containing all
previously identified single nucleotide mutations known
for drug resistance within the neuraminidase gene of
influenza virus. To address this issue, we produced long
synthetic oligos containing known influenza A resistance
mutations, and showed them to be effective as controls
in LCR. Further, they can also serve as templates in
real-time PCR and RCA [23,9].
T h eu s eo ff u l l ys y n t h e t i co ligonucleotides as positive
control material has been described recently [16]. How-
ever, there were limitations as to the length of the oligo-
nucleotide, which was generally unable to reach more
than 130 bases. In many situations, for instance in the
case of drug resistance mutations, nucleotide
Figure 2 Ligase chain reaction testing standard containing resistance template at various levels. A: N1: 274Tyr (resistance)/His (wild type);
B: H5N1: 274Tyr (resistance)/His (wild type). C: N2:119Val(resistance)/Glu(wild type), D: N2:292Lys(resistance)/Arg(wild type). After 10 cycleo f
ligation reaction, the generation of positive product can be detected even in the presence of low-level of resistance mutation (~1%).
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ome and thus require larger fragments as standard tem-
plates. Here, we took a novel approach to creating long
artificial templates by taking advantage of primer-
dimers, which are usually considered a common labora-
tory problem. The binding of two long artificially
synthesized oligos generated a substrate for PCR and
was used to create long double-stranded DNA mole-
cules of about 170 bp. In most of the current diagnostic
studies (especially based on real time PCR and RCA),
150-240 bp would be sufficient to serve a template con-
trols. However, it is possible to use multiple long oligos
to synthesize even longer double-stranded DNA and up
to the full length of some important genes, if need be
[26,27], which is a significant advantage over any similar
technologies existing currently.
The most significant advantage of using synthetic oli-
gonucleotides is flexibility. Our approach has proven
that the use of laboratory safe artificial templates can be
a relatively cost effective, simple and efficient alternative
to difficult to acquire material related to an infection or
bioterrorism agent. The production of standard tem-
plates via the formation of oligo dimers and PCR using
synthetic oligos does not require the use of viral or bac-
terial strains and oligos of any desired sequence can be
made commercially. This approach may have the poten-
tial to produce a false-positive product due to contami-
nation and therefore caution may be necessary.
However, this problem can be solved by the introduc-
tion of exclusive restriction endonuclease digestion sites
in the artificial template, which would allow for rapid
confirmation of a false-positive result. Certain restriction
endonuclease (SmaI and BamHI) can be used directly in
the PCR buffer (without buffer exchange) and thus the
PCR product from the control can be easily and rapidly
d i s t i n g u i s h e df r o mt e s t i n gsamples. In addition, the
standard artificial template could be designed to be
slightly smaller or larger in size, which would allow for
direct visual identification of contamination with the
synthetic control.
Overall, this technology may have wide ranging appli-
cations and may revolutionize molecular diagnostics and
the use of multiplexing assays.
Methods
Reference strains
The reference strains of influenza A H1N1, H5N1 and
H3N2 used in this study had Genebank accession num-
bers: CY12306.1, DQ493076, CY016653, respectively.
Design and synthesis of long oligos
Long single-stranded oligonucleotides of 89-98 bases
were designed, each containing wild-type template or
drug resistance mutations (Table 1). After synthesis,
each oligonucleotide was PAGE purified (Sigma-Aldrich,
Sydney, Australia). Paired long oligos were designed car-
rying >20bp complementary sequences at their 3’ ends.
Generation of double-stranded DNA using long oligos
and Taq polymerase
20 pmol of each paired oligo was incubated with 2 U of
Taq DNA polymerase (Promega, Madison, USA), 1X
reaction buffer, 2.5 mM MgCl2,a n d0 . 4m Mo fd N T P s .
The reaction mix was incubated at 94°C for 30 seconds
followed by 55°C for 30 seconds and 72°C for 30 sec-
onds for 5 cycles. After the reaction, the end product
was run on a 2% agarose gel and visualized under UV
light with ethidium bromide staining.
During this process, the complementary sequences
located at 3’ end of the paired oligo would form a dimer
and in the presence of DNA polymerase and dNTP,
each oligo would extend its 3’ end using the second
oligo as a template (Figure 3).
Cloning of the double-stranded DNA
To ensure the purity of the standard template, the pro-
ducts were ligated into the pGEM-T Easy Vector System
II (Promega, Madison, USA) and transformed into com-
petent Escherichia coli JM109 cells, according to the
manufacturer’s protocol. Screening for the gene insert
was performed by quick lysis at 95°C of the E. coli cells
for 5 minutes, followed by PCR using 5 μlo ft h ec e l l
lysate as previously described [28].
Sequencing of cloned dsDNA and sequence analysis
The plasmid DNA from positive clones was extracted
using the QIAprep Spin Miniprep Kit according to the
manufacturer’s protocol (Qiagen, Melbourne, Australia).
The inserts were sequenced using Applied Biosystems
BigDye terminator chemistry version 3.1 (Foster City,
CA, USA), on an ABI Prism 373 DNA sequencer.
Sequences were identified using the FastA program
group accessed through Biomanager (http://biomanager.
info/).
Ligase Chain Reaction (LCR) in the detection of templates
containing resistance mutation
Liner templates containing resistance and wild type were
generated by PCR amplification of plasmid DNA, fol-
lowed by purification using Millipore PCR purification
plate (Millipore, Billerica, MA, USA). The linear PCR
products were quantitated using spectrophotometer and
dsDNA DNA copy number were estimated by DNA cal-
culator (http://www.uri.edu/research/gsc/resources/
cndna.html). 5 × 10
11 copies of standard templates were
used for testing the specificity of the LCR system. LCR
probes targeting resistance template were designed
(Table 2). Each template was targeted by four LCR
Wang et al. Virology Journal 2011, 8:405
http://www.virologyj.com/content/8/1/405
Page 5 of 7probes about 35-45nt with 2 of the probes having 5’ end
phosphorylation. Ligation of LCR probes to standard
templates was carried out by mixing the standard tem-
plate with 1pmol of each LCR probes, 2U of pfu DNA
ligase (Stratagene, Integrated Sciences, Cedar Creek, TX,
USA) in 20 mM Tris-HCl (pH 7.5), 20 mM KCl, 10
mM MgCl2, 0.1% Igepal, 0.01 mM rATP, 1 mM DTT
with total reaction volume of 25 μl. Multiple cycle liga-
tion was conducted to validate the specificity of the
probe in recognizing its corresponding template. The
reaction condition include one cycle of 5 min at 94°C to
denature the dsDNA followed 10 cycles of by 94°C 30 s
and 4 min ligation at 65°C. The final product were run
on 10% TBE gel (Invitrogen, Mount Waverley VIC Aus-
tralia) and visualized under UV light with ethidium bro-
mide staining.
List of abbreviations
NAI: Neuraminidase inhibitor; PCR: polymerase chain reaction; RLB:reverse
line blot hybridization; LCR: Ligase chain reaction; RCA: Rolling Circle
Amplification.
Figure 3 Schematic representation of generating large DNA molecule using synthetic oligonucleotide templates. (A) The formation of a
dimer from two synthetic oligonucleotide templates. (B) In the presence of dNTP and DNA polymerase, each oligonucleotide will extend its 3’
end using other oligo as a template and form double-stranded DNA molecules. (C) The theory can be further extended using multiple oligos
containing complementary sequences at the 5’-phospahte ends. (D) Upon DNA polymerase reaching the 5’ end an oligo where a second down
stream oligo is annealed, the adjacent 3’-hydroxy ends and 5’-phosphate (P) can be sealed by DNA ligase via nick-sealing reactions. This process
in theory can be used to generate a very large, double-stranded DNA fragment.
Table 2 LCR probes for resistance mutations detection
Mutation
type
Probe sequences
N2-119VAL 5’ AAGGGGACATCTGGGTGACAAGAGT 3’
5’
aP-NCCTTATGTGTCATGCGATCCTGACAA 3’
5’ ACCTTGTCAGGATCGCATGACACATAAGGNA 3’
5’ P-CTCTTGTCACCCAGATGTCCCCAC 3’
N2-292LYS 5’ ATGATATCCTGGTGTCAGATGTGTCTGCAA 3’
5’ P-RGACAACTGGAAAGGCTCCAATAGGC 3’
5’ CCCCTATTGGAGCCTTTCCAGTTGTCYT 3’
5’ P-TGCAGACACATCTGACACCAGGATATCGAG 3’
N1-274Y 5’ TGTTACTAAATCAATAGAGTTGAATGCACCCAATTTTT 3’
5’ P-ATTATGAGGAATGTTCCTGTTACCCACACAC 3’
5’ TTGTGTCTGGGTAACAGGAACATTCCTCATAATA 3’
5’ P-AAAATTGGGTGCATTCAACTCTATTGATTTAGTAACC
3’
H5N1-274Y 5’ TCGGTTAAATCAGTCGAATTGGATGCTCCTAATTATT 3’
5’ P-ACTATGAGGAATGCTCCTGTTATCCTGATG 3’
5’ TTGCATCAGGATAACAGGAGCATTCCTCATAGTA 3’
5’ P-ATAATTAGGAGCATCCAATTCG 3’
a. P- indicates 5’ phosphorylation
Wang et al. Virology Journal 2011, 8:405
http://www.virologyj.com/content/8/1/405
Page 6 of 7Acknowledgements
The authors gratefully acknowledge all colleagues who participated in this
project. This work was funded by the NHMRC grant 408114, 633027.
Author details
1Retroviral Genetics Laboratory, Centre for Virus Research, Westmead
Millennium Institute, Westmead Hospital, The University of Sydney,
Westmead, New South Wales 2145, Australia.
2Department of Infectious
Diseases and Immunology, University of Sydney, Blackburn Building, 2006
NSW Australia.
3Centre for Infectious Diseases and Microbiology (CIDM),
Institute of Clinical Pathology and Medical Research (ICPMR), Westmead,
New South Wales 2145, Australia.
Authors’ contributions
BW conceived, designed and conducted the study along with sequence
search, data analyses and manuscript writing. MS assisted with the assay
optimization, cloning, DNA sequencing. DD, AC and NS provided intellectual
input and manuscript writing. All authors have read and approved the
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 January 2011 Accepted: 16 August 2011
Published: 16 August 2011
References
1. Ford SM, Grabenstein JD: Pandemics, avian influenza A (H5N1), and a
strategy for pharmacists. Pharmacotherapy 2006, 26:312-322.
2. Thomas JK, Noppenberger J: Avian influenza: A review. American Journal
of Health-System Pharmacy 2007, 64:149-165.
3. Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y: High Level of
Genetic Compatibility between Swine-Origin H1N1 and Highly
Pathogenic Avian H5N1 Influenza Viruses. Journal of Virology 2010,
84:10918-10922.
4. Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM,
Klimov AI: Characterization of an influenza A H5N2 reassortant as a
candidate for live-attenuated and inactivated vaccines against highly
pathogenic H5N1 viruses with pandemic potential. Vaccine 2006,
24:6859-6866.
5. Qiao C, Tian G, Jiang Y, Li Y, Shi J, Yu K, Chen H: Vaccines developed for
H5 highly pathogenic avian influenza in China. Ann N Y Acad Sci 2006,
1081:182-192.
6. Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J,
Macken C, Hampson A, Webster RG, Amyord M, Zambon M:
Neuraminidase inhibitor susceptibility network position statement:
antiviral resistance in influenza A/H5N1 viruses. Antiviral Therapy 2005,
10:873-877.
7. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K,
Hayden FG, Sugaya N, Kawaoka Y: Resistant influenza A viruses in
children treated with oseltamivir: descriptive study. Lancet 2004,
364:759-765.
8. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC,
Phan TQ, Do QH, Guan Y, et al: Oseltamivir resistance during treatment of
influenza A (H5N1) infection. N Engl J Med 2005, 353:2667-2672.
9. Wang B, Dwyer DE, Blyth CC, Soedjono M, Shi HJ, Kesson A,
Ratnamohan M, McPhie K, Cunningham AL, Saksena NK: Detection of the
rapid emergence of the H275Y mutation associated with oseltamivir
resistance in severe pandemic influenza virus A/H1N1 09 infections.
Antiviral Research 2010, 87:16-21.
10. Kong FR, Gilbert GL: Multiplex PCR-based reverse line blot hybridization
assay (mPCR/RLB) - a practical epidemiological and diagnostic tool.
Nature Protocols 2006, 1:2668-2680.
11. Tong ZS, Kong FR, Wang B, Zeng XY, Gilbert GL: A practical method for
subtyping of Streptococcus agalactiae serotype III, of human origin,
using rolling circle amplification. Journal of Microbiological Methods 2007,
70:39-44.
12. Pourmand N, Diamond L, Garten R, Erickson JP, Kumm J, Donis RO,
Davis RW: Rapid and highly informative diagnostic assay for H5N1
influenza viruses. PLoS One 2006, 1:e95.
13. Millar BC, Xu JR, Moore JE: Molecular diagnostics of medically important
bacterial infections. Current Issues in Molecular Biology 2007, 9:21-39.
14. Belak S: Molecular diagnosis of viral diseases, present trends and future
aspects a view from the OIE collaborating centre for the application of
polymerase chain reaction methods for diagnosis of viral diseases in
veterinary medicine. Vaccine 2007, 25:5444-5452.
15. Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X,
Aranda FI, Massuti B: Detection of BRAF V600E mutation in colorectal
cancer: Comparison of automatic sequencing and real-time chemistry
methodology. Journal of Molecular Diagnostics 2006, 8:540-543.
16. Costabile M, Quach A, Ferrante A: Molecular approaches in the diagnosis
of primary immunodeficiency diseases. Hum Mutat 2006, 27:1163-1173.
17. Gunthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD: Comparative
performance of high-density oligonucleotide sequencing and
dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.
Aids Research and Human Retroviruses 1998, 14:869-876.
18. Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, Falloon J,
Davey RT, Dewar RL, Metcalf JA, et al: Selection and persistence of non-
nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients
starting and stopping non-nucleoside therapy. Aids 2006, 20:701-710.
19. Di Trani L, Bedini B, Donatelli I, Campitelli L, Chiappini B, De Marco MA,
Delogu M, Buonavoglia C, Vaccari G: A sensitive one-step real-time PCR
for detection of avian influenza viruses using a MGB probe and an
internal positive control. Bmc Infectious Diseases 2006, 6.
20. Petrich A, Mahony J, Chong S, Broukhanski G, Gharabaghi F, Johnson G,
Louie L, Luinstra K, Willey B, Akhaven P, et al: Multicenter comparison of
nucleic acid extraction methods for detection of severe acute
respiratory syndrome coronavirus RNA in stool specimens. J Clin
Microbiol 2006, 44:2681-2688.
21. LeProust EM, Peck BJ, Spirin K, McCuen HB, Moore B, Namsaraev E,
Caruthers MH: Synthesis of high-quality libraries of long (150mer)
oligonucleotides by a novel depurination controlled process. Nucleic
Acids Research 2010, 38:2522-2540.
22. Wang B, Potter SJ, Lin YG, Cunningham AL, Dwyer DE, Su YL, Ma XJ,
Hou YD, Saksena NK: Rapid and sensitive detection of severe acute
respiratory syndrome coronavirus by rolling circle amplification. Journal
of Clinical Microbiology 2005, 43:2339-2344.
23. Steain MC, Dwyer DE, Hurt AC, Kol C, Saksena NK, Cunningham AL, Wang B:
Detection of influenza A H1N1 and H3N2 mutations conferring
resistance to oseltamivir using rolling circle amplification. Antiviral Res
2009, 84:242-248.
24. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS,
Webster RG, Govorkova EA: Neuraminidase inhibitor-resistant influenza
viruses may differ substantially in fitness and transmissibility.
Antimicrobial Agents and Chemotherapy 2005, 49:4075-4084.
25. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A,
Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M:
Detection of influenza viruses resistant to neuraminidase inhibitors in
global surveillance during the first 3 years of their use. Antimicrobial
Agents and Chemotherapy 2006, 50:2395-2402.
26. Encke J, Putlitz JZ, Heintges T, Wands JR: Total chemical synthesis of the 3
‘ untranslated region of the hepatitis C virus with long
oligodeoxynucleotides. Journal of Virological Methods 1998, 74:117-121.
27. Stemmer WP, Crameri A, Ha KD, Brennan TM, Heyneker HL: Single-step
assembly of a gene and entire plasmid from large numbers of
oligodeoxyribonucleotides. Gene 1995, 164:49-53.
28. Potter SJ, Lemey P, Achaz G, Chew CB, Vandamme AM, Dwyer DE,
Saksena NK: HIV-1 compartmentalization in diverse leukocyte
populations during antiretroviral therapy. J Leukoc Biol 2004, 76:562-570.
doi:10.1186/1743-422X-8-405
Cite this article as: Wang et al.: Synthetic long oligonucleotides to
generate artificial templates for use as positive controls in molecular
assays: drug resistance mutations in influenza virus as an example.
Virology Journal 2011 8:405.
Wang et al. Virology Journal 2011, 8:405
http://www.virologyj.com/content/8/1/405
Page 7 of 7